BioCentury
ARTICLE | Clinical News

ZT-034: Phase I started

October 12, 2009 7:00 AM UTC

Zelos began a single-blind, crossover, U.S. Phase I trial to evaluate single doses of 3 subcutaneous formulations of ZT-034 vs. Forteo teriparatide from Eli Lilly and Co. (NYSE:LLY, Indianapolis, In...